Archived explainer. For the current picture see today's PRCT page.
PROCEPT BIOROBOTICS (PRCT) is up +6.64% in the latest session. Our newswire has captured 5 stories on PRCT across 2 sources in the last 36 hours, with AI sentiment reading bearish (avg 39/100).
PRCT stock is up 6.64% to $22.79 as of the latest trade. The move follows a wave of legal notices and analyst updates in the last 36 hours, with five stories from two sources highlighting a securities class action deadline on September 22, 2026. These developments appear to have driven investor interest and lifted the stock from a negative open.
Multiple law firms have alerted investors to a pending deadline for participation in a securities class action against PROCEPT BioRobotics. The lawsuits, filed by firms including Hagens Berman Sobol Shapiro LLP and Kaplan Fox Kilsheimer LLP, target investors who purchased shares between February 28, 2024, and February 25, 2026. These alerts have increased visibility for the stock, particularly as the deadline approaches. Additionally, the company affirmed its full-year 2026 sales guidance of $390 million to $410 million, aligning with the current estimate of $397.424 million. This guidance may have contributed to a more positive outlook.
Analyst coverage has also shifted in recent days. TD Cowen, Piper Sandler, and Evercore ISI Group have maintained Buy or Overweight ratings but lowered price targets to $28, $25, and $23, respectively. William Blair downgraded the stock to Market Perform. These updates reflect a mixed but not bearish stance toward the stock.
The stock opened at $21.17, a 0.9% gap down from the prior close of $21.37. It reached a session high of $22.84 at 10:25 AM ET and closed the session at $22.82. The volume of 0.3 million shares is below the 3-month average, suggesting limited institutional participation. The stock is currently trading within its 52-week range of $16.66 to $41.51. On September 4, it printed one fresh 52-week low and 16 fresh 52-week highs, indicating a volatile tape.
Recent insider transactions include a purchase by CEO Larry L. Wood on August 7 and sales by EVP CTO Barry L. Templin and EVP CFO Kevin Waters on June 8. The insider filings show $498K in buys and $28K in sells over the last 90 days.
The stock is currently unprofitable with a TTM EPS of -1.95 and a net margin of -32.5%. Revenue has increased 22.7% TTM. Investors should monitor the September 22, 2026, deadline for the securities class action lawsuits and any changes in analyst coverage or earnings guidance.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
San Francisco, California--(Newsfile Corp. - September 4, 2026) - Hagens Berman Sobol Shapiro LLP alerts investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that a securities class action...
Kaplan Fox announces a securities class action against PROCEPT BioRobotics (NASDAQ: PRCT) for purchasers from Feb. 28, 2024 to Feb. 25, 2026....
New York, New York--(Newsfile Corp. - September 3, 2026) - Kaplan Fox Kilsheimer LLP announces that a...
LOS ANGELES, Sept. 03, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf...
Shareholder Notice: Erasca . (NASDAQ: ERAS); Hub Group (NASDAQ: HUBG); Hyliion Holdings (NYSE: HYLN); and PROCEPT BioRobotics (NASDAQ: PRCT)...
More on PRCT: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier PRCT move explainers: 2026-09-08 · 2026-09-04